NASDAQ: LYRA - Lyra Therapeutics, Inc.

六个月盈利: -31.96%
部门: Healthcare

促销时间表 Lyra Therapeutics, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

更多详情
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2020-05-01
ISIN US55234L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://lyratherapeutics.com
Цена ао 6.13
每日价格变化: +5.48% (0.1806)
每周价格变化: +5.83% (0.18)
每月价格变化: +0.2632% (0.19)
3个月内价格变化: -28.3% (0.2657)
六个月内的价格变化: -31.96% (0.28)
每年价格变化: -96.36% (5.24)
3年内价格变化: -95.81% (4.55)
5年内价格变化: 0% (0.1905)
10年价格变化: 0% (0.1905)
年初以来价格变化: -9.37% (0.2102)
所有参数

低估

姓名 意义 年级
P/S 159.19 1
P/BV 2.77 6
P/E 0 0
EV/EBITDA -3.87 0
全部的: 3.5

效率

姓名 意义 年级
ROA, % -43.96 0
ROE, % -70.1 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.412 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 29.83 4
盈利能力 Ebitda, % 295.45 10
盈利能力 EPS, % -51.03 0
全部的: 6.8
更多详情

机构 体积 分享, %
Perceptive Advisors LLC 12757562 21.35
Nantahala Capital Management, LLC 8100436 13.56
Vestal Point Capital, LP 3000000 5.02
Point72 Asset Management, L.P. 3000000 5.02
Citadel Advisors Llc 2861255 4.79
Samsara BioCapital, LLC 2780261 4.65
VR Adviser, LLC 2575593 4.31
Rosalind Advisors, Inc. 1888720 3.16
PURA VIDA INVESTMENTS, LLC 1413242 2.37
Ikarian Capital, LLC 1254384 2.1

ETF 分享, % 本年盈利能力, % 股息, %
iShares Micro-Cap ETF 0.00348 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00096 38.04 0.6026
ProShares UltraPro Russell2000 0.0003 89.82 1.47873
ProShares Hedge Replication ETF 0.00008 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



导师 职称 支付 出生年份
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (72 年)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (60 年)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (56 年)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (52 年)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (52 年)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (67 年)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

地址: United States, Watertown. MA, 480 Arsenal Way - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://lyratherapeutics.com